Posted by Michael Wonder on 16 May 2022
scPharmaceuticals announces FDA acceptance of Furoscix new drug application
16 May 2022 - PDUFA action date set for October 8, 2022.
scPharmaceuticals today announced that the Company’s new drug application for Furoscix, a proprietary formulation of furosemide delivered via an on-body infusor for the treatment of congestion in patients with worsening heart failure, has been accepted for filing by the U.S. FDA.
